DK1355669T3 - Forbedret kognitiv træning - Google Patents

Forbedret kognitiv træning

Info

Publication number
DK1355669T3
DK1355669T3 DK01963877.4T DK01963877T DK1355669T3 DK 1355669 T3 DK1355669 T3 DK 1355669T3 DK 01963877 T DK01963877 T DK 01963877T DK 1355669 T3 DK1355669 T3 DK 1355669T3
Authority
DK
Denmark
Prior art keywords
methods
cognitive training
cognitive
improved cognitive
neuronal activity
Prior art date
Application number
DK01963877.4T
Other languages
English (en)
Inventor
Filippo Cavalieri
Timothy P Tully
Original Assignee
Cold Spring Harbor Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab filed Critical Cold Spring Harbor Lab
Application granted granted Critical
Publication of DK1355669T3 publication Critical patent/DK1355669T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N1/00—Electrotherapy; Circuits therefor
    • A61N1/18—Applying electric currents by contact electrodes
    • A61N1/20—Applying electric currents by contact electrodes continuous direct currents
    • A61N1/30—Apparatus for iontophoresis, i.e. transfer of media in ionic state by an electromotoric force into the body, or cataphoresis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • G—PHYSICS
    • G09—EDUCATION; CRYPTOGRAPHY; DISPLAY; ADVERTISING; SEALS
    • G09B—EDUCATIONAL OR DEMONSTRATION APPLIANCES; APPLIANCES FOR TEACHING, OR COMMUNICATING WITH, THE BLIND, DEAF OR MUTE; MODELS; PLANETARIA; GLOBES; MAPS; DIAGRAMS
    • G09B19/00—Teaching not covered by other main groups of this subclass
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Business, Economics & Management (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Theoretical Computer Science (AREA)
  • Educational Administration (AREA)
  • Physics & Mathematics (AREA)
  • Entrepreneurship & Innovation (AREA)
  • General Physics & Mathematics (AREA)
  • Educational Technology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Electrotherapy Devices (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of Eletrric Generators (AREA)
  • Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
DK01963877.4T 2000-08-10 2001-08-10 Forbedret kognitiv træning DK1355669T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22422700P 2000-08-10 2000-08-10
PCT/US2001/025048 WO2002013867A2 (en) 2000-08-10 2001-08-10 Augmented cognitive training

Publications (1)

Publication Number Publication Date
DK1355669T3 true DK1355669T3 (da) 2011-11-21

Family

ID=22839775

Family Applications (1)

Application Number Title Priority Date Filing Date
DK01963877.4T DK1355669T3 (da) 2000-08-10 2001-08-10 Forbedret kognitiv træning

Country Status (8)

Country Link
US (6) US7947731B2 (da)
EP (3) EP1355669B1 (da)
AT (1) ATE526020T1 (da)
AU (1) AU2001284792A1 (da)
DK (1) DK1355669T3 (da)
ES (1) ES2373540T3 (da)
PT (1) PT1355669E (da)
WO (1) WO2002013867A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7868015B2 (en) 2000-08-10 2011-01-11 Cold Spring Harbor Laboratory Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
US7947731B2 (en) 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US9931318B2 (en) 2003-04-08 2018-04-03 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US8153646B2 (en) 2000-08-10 2012-04-10 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
CN1638775A (zh) * 2002-01-04 2005-07-13 亨利福尔德健康组织 治疗疾病和损伤用的氧化氮供体
EP2177626B1 (en) * 2002-08-19 2013-12-18 Dart NeuroScience (Cayman) Ltd Screening methods for cognitive enhancers
DK1540335T3 (da) 2002-08-19 2010-07-26 Helicon Therapeutics Inc Screeningsfremgangsmåder til kognitive forstækere
US7725192B2 (en) * 2005-10-12 2010-05-25 The General Hospital Corporation Methods of increasing learning rate
EP2377533A3 (en) * 2006-05-19 2012-02-22 Helicon Therapeutics, Inc. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US9990859B2 (en) 2008-01-17 2018-06-05 Speech Buddies, Inc. Intraoral tactile biofeedback methods, devices and systems for speech and language training
WO2009092107A2 (en) * 2008-01-17 2009-07-23 Articulate Technologies, Inc. Methods and devices for intraoral tactile feedback
BRPI0916228A2 (pt) * 2008-07-18 2015-11-03 Dart Neuroscience Llc métodos e sistemas para avaliação de agentes de memória
US9499562B2 (en) 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds
US9265458B2 (en) 2012-12-04 2016-02-23 Sync-Think, Inc. Application of smooth pursuit cognitive testing paradigms to clinical drug development
US9380976B2 (en) 2013-03-11 2016-07-05 Sync-Think, Inc. Optical neuroinformatics
AU2014241430B2 (en) 2013-03-14 2018-04-26 Dart Neuroscience (Cayman) Ltd. Substituted pyridine and pyrazine compounds as PDE4 inhibitors
NZ711598A (en) 2013-03-14 2016-09-30 Dart Neuroscience Cayman Ltd Substituted naphthyridine and quinoline compounds as mao inhibitors
EP3134413B1 (en) 2014-04-23 2019-09-11 Dart NeuroScience (Cayman) Ltd. Substituted [1,2,4]triazolo[1,5-a]pyrimidin-7-yl compounds as pde2 inhibitors
EP3134406A1 (en) 2014-04-24 2017-03-01 Dart Neuroscience (Cayman) Ltd Substituted 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole and 4,5,6,7-tetrahydro-2h-pyrazolo [4,3-c]pyridine compounds as glyt1 inhibitors
RU2017112054A (ru) * 2014-09-17 2018-10-17 Дарт Нюросайенс (Кайман) Лтд. Ингибиторы mao-b и реабилитация
TWI568737B (zh) 2014-11-05 2017-02-01 達特神經科學（開曼）有限責任公司 作為ｐｄｅ２抑制劑之經取代的５－甲基－［１，２，４］三唑并［１，５－ａ］嘧啶－２－胺化合物
EP3215500A1 (en) 2014-11-05 2017-09-13 Dart NeuroScience (Cayman) Ltd. Substituted azetidinyl compounds as glyt1 inhibitors
WO2016179428A2 (en) 2015-05-05 2016-11-10 Dart Neuroscience, Llc Cognitive test execution and control
EP3562828B1 (en) 2016-12-28 2026-03-18 Dart Neuroscience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
US11685745B2 (en) 2017-07-12 2023-06-27 Dart Neuroscience, Llc Substituted benzoxazole and benzofuran compounds as PDE7 inhibitors
MX2020005447A (es) 2017-11-27 2020-12-03 Dart Neuroscience Llc Compuestos de furanopirimidina sustituida como inhibidores de pde1.
US11365191B2 (en) 2018-02-28 2022-06-21 Dart Neuroscience, Llc Substituted cyclohexyl compounds as NOP inhibiiors
GB201911024D0 (en) * 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
EP4252750A1 (en) 2022-03-31 2023-10-04 Leibniz-Institut für Neurobiologie Pharmaceutical preservation of creb activation in the treatment of alzheimer's disease
CN120022498B (zh) * 2025-04-21 2025-07-15 吕梁学院 一种基于应用心理学记忆判断训练方法及训练装置

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4686225A (en) * 1986-04-29 1987-08-11 American Home Products Corporation (Del.) Vinpocetine for pulmonary hemorrhage and edema
KR920702621A (ko) 1989-06-13 1992-10-06 스튜어트 알. 슈터 단핵세포 및/또는 마크로파지에 의한 인터루킨-1 또는 종양회사인자 생성의 억제
AU5921890A (en) 1989-06-13 1991-01-08 Smithkline Beecham Corporation Monokine activity interference
JP2578001B2 (ja) 1989-12-11 1997-02-05 明治製菓株式会社 抗痴呆薬
US5547979A (en) * 1992-03-30 1996-08-20 Smithkline Beecham TNF inhibition
AU678158B2 (en) 1992-04-10 1997-05-22 Fox Chase Cancer Center Transcription control element for increasing gene expression in myoblasts
DE4310699A1 (de) * 1993-04-01 1994-10-06 Merck Patent Gmbh Thiadiazinone
EP0781335A1 (en) 1994-10-07 1997-07-02 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
US5929223A (en) 1994-10-07 1999-07-27 Cold Spring Harbor Laboratory Cloning and characterizing of genes associated with long-term memory
DK0813411T3 (da) * 1995-02-15 2002-05-13 Takeda Chemical Industries Ltd Anvendelse af vincopetinderivater til hæmning af dannelse eller afsondring af amyloid -protein
ES2097703B1 (es) * 1995-04-12 1997-12-01 Decox S L Una nueva composicion estimulante de la actividad cerebral basada en alcaloides de nucleo de eburnamenina, y sus metodos de preparacion.
US5882203A (en) * 1995-05-31 1999-03-16 Correa; Elsa I. Method of detecting depression
US5801030A (en) 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
EP0936923B1 (en) 1996-11-15 2003-12-17 Kennedy Institute Of Rheumatology SUPPRESSION OF TNFalpha AND IL-12 IN THERAPY
US6258794B1 (en) * 1999-12-14 2001-07-10 The Mclean Hospital Corporation Treatment of mental conditions including depression
US6270077B1 (en) * 1999-12-20 2001-08-07 Gene D. Cohen Non-competitive memory enhancement game
US7947731B2 (en) 2000-08-10 2011-05-24 Cold Spring Harbor Laboratory Augmented cognitive training
US20040224316A1 (en) * 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US20040053810A1 (en) 2002-08-16 2004-03-18 Tully Jo Anne Liquid laundry compositions comprising silicone additives
DK1540335T3 (da) 2002-08-19 2010-07-26 Helicon Therapeutics Inc Screeningsfremgangsmåder til kognitive forstækere
EP2377533A3 (en) * 2006-05-19 2012-02-22 Helicon Therapeutics, Inc. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
US9499562B2 (en) * 2012-06-18 2016-11-22 Dart Neuroscience (Cayman) Ltd. Substituted thiophene- and furan-fused azolopyrimidine-5-(6H)-one compounds

Also Published As

Publication number Publication date
US20110224146A1 (en) 2011-09-15
US20130274704A1 (en) 2013-10-17
EP2305353A1 (en) 2011-04-06
ES2373540T3 (es) 2012-02-06
PT1355669E (pt) 2012-01-02
US8455538B2 (en) 2013-06-04
US20020076398A1 (en) 2002-06-20
US20110224287A1 (en) 2011-09-15
US20150141441A1 (en) 2015-05-21
WO2002013867A3 (en) 2003-08-07
EP1355669A2 (en) 2003-10-29
EP2316531A1 (en) 2011-05-04
WO2002013867A2 (en) 2002-02-21
EP1355669B1 (en) 2011-09-28
AU2001284792A1 (en) 2002-02-25
ATE526020T1 (de) 2011-10-15
US7947731B2 (en) 2011-05-24
US20130164721A1 (en) 2013-06-27

Similar Documents

Publication Publication Date Title
ATE526020T1 (de) Gesteigertes kognitives training
ATE412642T1 (de) Inhibitoren von p-38-kinase
DE60219961T8 (de) Behandlung von neurologischen funktionsstörungen mit fructopyranosesulfamaten und erythropoetin
CY1107054T1 (el) Ενωσεις διτοσυλικου αλατος κιναζολινης
DK1287364T3 (da) Diagnostisk og terapi til makulære degenerationsrelaterede lidelser
WO1999045949A3 (en) Use of follistatin to modulate gdf-8 and bmp-11
AU2002312254A8 (en) Tbc1d1s as modifiers of the p53 pathway and methods of use
NO20023423D0 (no) Hjerne-, spinal- og nerveskade behandling
DK1303495T3 (da) Substituerede 5-alkylnylpyrimidiner med neurotrofisk aktivitet
CY1112817T1 (el) Ομοχαρριγκτονινη μονη ή συνδυασμενη με αλλους παραγοντες για χρηση στην αγωγη της χρονιας μυελογενους λευχαιμιας, ανθεκτικης ή μη ανεκτικης σε αναστολεις πρωτεϊνικης κινασης εκτος του sτi 571
WO2003030823A3 (en) Combinations for the treatment of immunoinflammatory disorders
EE200300559A (et) Osteopontiini kasutamine neuroloogiliste haigusteraviks ja/või vältimiseks
WO2003015713A3 (en) Treatment of glial tumors with glutamate antagonists
WO2004091609A3 (en) Phosphodiesesterase 4 inhibitors for the treatment of a cognitive deficit
ATE439363T1 (de) Imidazo 2,1-b -1,3,4-thiadiazole sulfonamides
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
WO2001091745A3 (en) Use of epoxyeicosatrienoic acids in the treatment of cerebrovascular conditions
GB0015228D0 (en) Substituted nitrated catechols, their use in the treatment of some central and peripheral nervous system disorders
YU89103A (sh) Novi postupak lečenja opsesivno-kompulsivnog poremećaja (okp) i poremećaja povezanih sa okp-om, korišćenjem gvg-a
WO2020080865A3 (ko) 치매 또는 우울증과 같은 뇌질환의 예방 및 치료를 위한 자기장 자극기를 장착한 마사지 장치 및 방법
DE602004013540D1 (de) Hemmung des cd95 liganden/rezeptor-systems zur behandlung von neurologischen erkrankungen und verletzungen
BR0210678A (pt) Carbamatos de 2-heterocìclicos-1,2-etanodióis
CY1116647T1 (el) Προσαυξημενη γνωσιακη εκπαιδευση
WO2004058154A3 (en) Method of identifying therapeutic agents
DK1133297T3 (da) Ny terapeutisk anvendelse af 1,6-dimethyl-8beta-hydroxymethyl-10alpha-methoxyergolin